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Abstract 
The search for new treatments and testing of new ideas begins in the laboratory and then established in clinical 
research settings. Studies addressing the same therapeutic problem may produce conflicting results hence 
Randomized Clinical Trial is regarded as the most valid method for assessing the benefits and harms of healthcare 
interventions. The next challenge face by the medical community is the validity of such trials as theses tend to 
deviate from the truth because of various biases. For the avoidance of the same it has been suggested that the 
validity or quality of primary trials should be assessed under blind conditions. Thus blinding, is a crucial method 
for reducing bias in randomized clinical trials. Blinding can be defined as withholding information about the 
assigned interventions from people involved in the trial who may potentially be prejudiced by this knowledge. In 
this article we make an effort to define blinding, explain its chronology, hierarchy and discuss methods of blinding, 
its assessment, its possibility, un-blinding and finally the latest guidelines. 
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Introduction  
A clinical trial is one of the final stages of long and 
vigilant research procedures. Gaining irrefutable 
knowledge from clinical research data becomes 
impossible due to studies producing conflicting 
results; hence there is need of Randomized Clinical 
Trial (RCT), the most valid method for assessing the 
benefits and harms of healthcare interventions (1). 
One challenge to the validity of RCT is the propensity 
for various biases. It has been suggested that the 
validity of trials should be assessed under blind 
conditions.  
Aims & Objectives 
To understand blinding and bring together all the 
aspects related to it. 
Material and Methods 
As this is a review article, which has used only the 
information available in public domain, so there is no 
ethical issues involved. 
Results 
Definition: Blinding came into existence in very early 
in research experiments with the French Academy of 
Sciences originated the first recorded blind 
experiments in 1784 (2). First double-blind study was 
done by Rivers (1908) in experimental psychology. 
The term "blind test" was first used by Gold 1946 (3). 
Blinding has been applied since time immemorial, 
but the enigmatic nature of blinding remains, as it is 
still a difficult feat to understand or to actually utilize 
in a RCT.  
Blinding is a crucial method for reducing bias in 
randomized clinical trials. Blinding can be defined as 
withholding information about the consigned 
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method of treatment which is likely to prejudice the 
people involved in the trial. Blinding is prevention of 
bias in Clinical trials especially when looking at 
subjective outcomes (4). Simply stating the term 
blinding refers to keeping all trial participants (the 
patients, investigators or those collecting and 
assessing outcome data) unaware of the dispensed 
intervention, so that this knowledge does not 
influence them. “Masking” and “blinding” are 
synonymous terms, although the word masking may 
sometimes be preferable especially to avoid 
confusion in ophthalmologic trials where blindness 
can be an outcome. Though blinding is preferred 
term because it pervades all guidelines, is universally 
recognized (5). 
Chronology of Blinding in RCT 
Blinding is used in research studies that compare two 
or more types of interventions in same disease. 
Blinding is usually done after successful 
randomization and allocation concealment. 
Randomization 
Creation of an unpredictable allocation series is the 
first step of randomization which is of paramount 
importance in a RCT. Randomization is a pre-defined 
strategy for generating the allocation sequence. To 
prevent the patients and researchers from 
anticipating the received treatments and thereby 
influencing the trial outcome is the primary purpose 
of randomizing patients. 
Allocation concealment 
After the creation of an unpredictable allocation 
series, the next step is to concealing it at least until 
patients has been assigned to their groups or 
respective treatment arms. This would prevent the 
collapse of randomization and has been termed as 
allocation concealment. Allocation concealment can 
be confused with blinding, though it’s completely 
different from blinding. It just seeks to eliminate 
selection bias, that is who is selected as a participant 
and is assigned which treatment arm. Also, it is 
possible to conceal the generated randomization in 
every trial. Blinding on the other hand takes care of 
what happens after group assignment, what is the 
treatment being given to respective group. So by 
contrast, blinding relates to what happens after 
randomization and seeks to reduce ascertainment 
bias (assessment of outcome). Unlike allocation 
concealment blinding is a difficult feat to attain and 
is not always possible. 
Types of trials  
The medical trials can be broadly classified into three 
types viz open trials, partially blind and blind trials 
(6). 
Open trials/open label are where all participants and 
investigators know who is getting which intervention 
e.g. medical vs. surgical treatments. Such trials are 
considered useful for dose ranging studies. For 
example a randomized, open-label clinical trial on 
cognitive effects of antipsychotic drugs in first-
episode schizophrenia and schizophreniform 
disorder was carried out. In this particular study 498 
patients with schizophrenia were randomly assigned 
to open-label Antipsychotic Drugs (7). Here the 
participants and the treatment providers knew the 
treatment being provided to the two groups. 
Similarly, open trials are used for pilot studies 
assessing the actual efficacy of medications (8). 
A partially blind trial is usually conducted during 
Phase II, of any vaccine development where 
participants and providers are blind to vaccine but 
not to schedule (9). Last in this list is the holy grail of 
trials -the blind trials. Here we would be discussing 
more about the blind trials, their history, Hierarchy, 
why blinding is done, how we accomplish it and how 
to assess it. 
Hierarchy of Blinding  
It is advisable for the researcher to blind at least four 
groups of individuals involved in trials (10). These can 
be namely the participants, clinicians /surgeons, 
outcome assessor (data collectors and critical 
evaluator) and the data analysts. 
Hierarchy of Blinding includes the various types 
based on individuals blinded. 
 Single blind: where only participant/ only 
clinician is blinded to assigned intervention or 
treatment 
 Double blind: Both participant and clinician/ 
health care provider are blinded to treatment 
 Triple blind: participants, clinician and outcome 
assessors blinded to treatment 
 Quadruple blind: participants, clinician, 
outcome assessors and statistical analyst blinded 
to treatment 
In Single blind trial usually participants are blind to 
the treatment given. When it is unacceptable 
ethically to give placebo treatment then blinding the 
treating clinician would serve the purpose. 
Justification for single blind scenarios is possible only 
when the carrying out of double-blind becomes 
unfeasible due to adjustments required in 
medication dose or potential side effects which are 
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unknown and non-quantified. For example, in a 
prospective randomized a comparison between 
laparoscopic and small-incision cholecystectomy 
conducted in 200 patients. The patients were 
randomized in the operating theatre and an 
aesthetic technique and pain-control methods were 
standardized and identical wound dressings were 
applied in both groups. Here it was the patients who 
were blinded as blinding of surgeons were not 
possible.  
Knowledge of group assignment to participants may 
affect their conduct in the trial (11). For example, 
one who is aware of not receiving active treatment 
may pursue supplementary treatment outside of the 
trial, may vary his/her responses to subjective 
measures of outcome and is more inclined to leave 
the trial. Those receiving an experimental 
intervention may have preconceived notions about 
the effects of particular treatment, thus defeating 
the purpose of trial. This also eliminates Hawthorne 
Effect (12) which states that attention alone 
produces results. That is why an equal attention 
control design is used in clinical trials. To “blind” 
patient placebo can be used, it is a pill of same size, 
color, shape as treatment or the other treatments 
"shammed" as nearly as possible. 
In Double blind trial both the participant and clinician 
are blinded. Patient is given a bar-code or code. The 
medications also are having a bar-code/ code. 
Blinding the Investigator/clinician eliminates 
Investigator bias (13). One very interesting example 
of a double blinding is trial by Bollinger et al (14) 
which was looking at reduction of smoking using oral 
nicotine inhalers instead of cigarettes. In this study 
400 healthy volunteers were included and provided 
either active or placebo inhalers by pharmacists (not 
part of trial) using a computer generated list which 
has randomized participants. Thus both the both 
participants and health providers were blinded. 
Because of blinding the investigators are also less 
likely to convey their penchants or attitudes to 
participants, or to differentially provide additional 
treatments, or to adjust dose of the treatment being 
tested and finally influencing which patient should 
leave or continue in the trial. 
In triple blind trial the Participants, clinician and 
outcome assessors are blinded. One example is a 
triple-blind, sham-controlled study of Low-level laser 
therapy facilitates superficial wound healing in 
humans by Hopkins et al (15) where the subject, 
clinician, and investigator examining the wounds 
were blinded as to which treatment group was the 
sham. The definition of sham is a treatment or 
procedure that is performed as a control and that is 
similar to but omits a key therapeutic element of the 
treatment or procedure under investigation. Here 
Low level laser beam therapy was given to one group 
of patients and sham procedure to other group. It 
was only after the data analysis, the manufacturer 
revealed the true treatment head. The need of 
blinding the outcome assessor is eminent since 
unwittingly (or even intentionally) they may exercise 
more care about one type of responses or 
measurements such as those supporting a particular 
hypothesis. 
In Quadruple blind trial the participants, clinician, 
outcome assessors and statistical analyst are 
blinded. Until the entire analysis has been completed 
the data analyst should not be aware of the 
progression or expected results of intervention. At 
the level of statistical analysis, a bias may be 
introduced by the selective use and reporting of 
various statistical tests, though this may or may not 
be an unintentional (16,17) nevertheless the effects 
are manifold. One such example of study using 
blinding at each stage is an experiment conducted by 
Ghajari et al (18) comparing the radiographic 
findings and success rates of direct pulp capping with 
different substances. Radiographic and clinical 
successes were evaluated at 20-month follow-up by 
a calibrated dentist, radiologist and a statistician 
who were also blind to the type of used biomaterial.  
Methods of blinding in Pharmacological trials  
Simplest methods for of blinding are possible in 
Pharmacological trials.  
For medications to be applied or taken orally a 
common preparation can be done to produce similar 
looking medications (both having active ingredient 
and those having none) like similar capsules, tablets, 
or similar bottles are commonly used techniques. 
Researchers have used specific flavors such as sugar 
or peppermint masking the characteristic taste of 
the active ingredients. For treatments administered 
by care providers, like intravenous injections, 
preparation of opaque dispensers or containers to 
adequately conceal different appearances of fluid 
within can be used. The provided treatment and 
placebo should have identical appearance (size, 
color, weight, feel, odor, etc.), same package, same 
label and same instruction. 
It has also been suggested that the injection of 
placebo or active treatment can be administered by 
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unblended operator not involved in any other study 
procedure. 
Blinding in Non-Pharmacological trials 
Sham procedures can be used for assessing a device 
or gauging the success of a surgical procedure. The 
sham procedures can be simulation of the 
intervention under consideration; including 
“standardizing” the postoperative care. It is also 
recommended that the researcher can use identical 
inactivated machine, same light noise sensation, 
same instructions, same duration and frequency, 
patient’s position, same precautions like protective 
goggles in both groups.  
The sham procedures for studies involving the 
participation of patients were either an intervention 
of very similar nature. For example, some studies 
involved the use of hands-on set of man oeuvres to 
simulate treatment or others have used sham 
procedures using identical apparatus or machines 
such as a switched off machine or use of switched on 
machine having a barrier to block the treatment or 
modifying the position of patient in placebo arm so 
that the targeted area is not exposed to the 
treatment (19).For example, a study assessing use of 
high-strength magnetic application for treatment of 
knee osteoarthritis has used a misdirected magnetic 
field (facing away from the knee joint) as placebo.  
Blinding in surgical trials 
Blinding is indisputably more difficult to achieve in 
surgical trials, since surgical treatments would often 
result in tell-tale incisions and scars differing 
between groups or there is simply a comparison 
between surgical and non-operative intervention. In 
such scenario it is much advisable to blind the other 
members of the team including those proving post-
operative care like nursing staff and interacting with 
patients after surgery like dieticians and other 
doctors. Rationale of using strategies like 
concealment of scars or digitally varying the 
radiological features is to masquerade the type of 
scar/implant. 
Assessment of Blinding  
Accomplishment of perfect blinding is of 
fundamental importance in many trials. It is assumed 
to be so and the results become questionable if this 
vital assumption is debased. Several ways are 
proposed in literature to evaluate blinding, but none 
of the suggested methods are being used commonly 
or can be regarded as gold standards. But truthfully 
reporting the blinding efforts used can help the 
readers to judge those efforts. Some straightforward 
steps have been widely quoted in literature including 
step one of unambiguously stating who was blinded 
and providing the mechanism used, as was done in a 
double blind study by Roddy et al on use of 
nonoxynol 9 film, aiming to reduce sexual 
transmission of diseases male-to-female (20). This 
publication clearly mentions that neither the women 
nor the care giving staff knew which group of 
patients were using appropriated films, and also 
states that the placebo and treatment films were 
indistinguishable in appearance. Step two includes 
assessment of blinding using preformed 
questionnaires. Lastly one can also use statistical 
assessment of Blinding (21, 22). The two statistical 
methods, James' blinding index and Bang's blinding 
index are currently available. 
Possibility of Blinding  
Undoubtedly Blinding is not always a possibility. 
Sometimes single blind trials or even open trials 
cannot be avoided. Full blinding is often impossible 
in trials of different approaches of patient 
management, blinding in a surgical intervention or 
device study, surgical procedures having 
characteristic scar, or a treatment having 
characteristic side effects. 
If it is almost impossible to blind the participants or 
the treating clinician then the researcher should be 
innovative and do the best they can, promote use of 
hard outcomes rather than subjective ones like 
questionnaires. If possible the researcher can Blind 
outcome assessors, and finally on completion can 
measure degree of un-blinding and lastly 
acknowledge the limitations. 
Un-blinding 
In life threatening situations and emergencies 
involving trial participants, unblinding can be done. 
Even for a single subject the blinding of a trial should 
be done only when knowledge of the treatment 
assignment is a must for the subject's care. Any 
breaking of the blind, either intentional or 
unintentional should be reported correctly 
mentioning the procedure and timing. For example, 
in a double-blind randomized trial having 265 
subjects conducted by Bisognano et al to determine 
the effect of baro-reflex activation therapy on 
systolic blood pressure in resistant hypertension, 
three subjects met the emergency un-blinding 
criteria of hypertensive emergency with confirmed 
diastolic BP of 120 mm Hg or greater with evidence 
of accelerated symptoms of end-organ damage and 
had their treatment assignment revealed (23). 
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Current scenario of Blinding 
There has been a lot of debate in the scientific 
community about the terms. A recent review 
including 200 trials with a survey of authors was 
conducted regarding how blinding is reported in 
clinical trials and how lack of reporting relate to lack 
of blinding. They found that One-hundred and fifty-
six (78%) articles described trials as ‘double blind’ 
but only a meagre 3 (2%): explicitly described 
blinding. They also revealed that twenty (19%) 
‘Double blind’ trials: had not blinded patients, health 
care providers or data collectors. These results 
indicate a lack of correct concepts and their faulty 
implementations. 
Consolidated Standards of Reporting Trials 
(CONSORT) Guidelines were first made available in 
print in year 1996 and were updated in 2010. The 
statement provides clear cut checklist and flow 
diagrams for researchers. The recent consort 
guidelines suggest that terms like single, double 
blind etc. are vague and their use should be 
abandoned. The investigators should rather as to 
who was blinded and how they achieved the 
blinding. The guidelines (24) have been formulated 
to perk up the quality of reporting of various RCTs.  
Implications 
Human behavior is known to be swayed by what we 
discern or believe. In research there is a particular 
risk of propel particular set of findings, especially 
when subjective assessment is there resulting in 
biased outcomes. Blinding is used to eradicate such 
a bias. The significance of blinding may differ in 
different circumstances. This paper emphasizes that 
it may jeopardise results if ample blinding measure 
and techniques are not used. This seems to be 
challenging the veracity of researchers, but notably 
such biases are often subconscious. Trials not using 
appropriate blinding show larger treatment effects 
on the other hand good blinding strategies makes 
less biased outcomes and helps preserve the 
credibility of results. 
Conclusion 
Blinding is critical for Randomized controlled trial 
(RCTs) for alleviating biases and must be practiced as 
far as possible for generating the valid data. Latest 
reports show that currently researchers are neither 
practicing the binding appropriately nor they are 
reporting it clearly in their published data.   
Recommendation  
Blinding is an important aspect for Randomized 
controlled trial (RCTs) for removing the biases. Hence 
while undertaking RCTs researchers must ensure 
proper allocation concealment (before 
randomization) and blinding as appropriate. 
Researchers must also report the process of blinding 
clearly while publishing the research article. 
Relevance of the study 
This article will help the researchers and students to 
understand the importance and correct process of 
ensuring blinding in the study. This would further 
help in generating valid data. 
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